secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-040980
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Q2 net loss $9.6M; CAN-2409 NSCLC Fast Track; cash runway through Q2 2024
--------------------------------------------------------------------------------

- Net loss of $9.6M in Q2 2023 vs $4.1M in Q2 2022, driven by higher R&D costs and warrant liability change.
- Cash and equivalents $51.9M as of June 30, 2023; expected to fund operations into Q2 2024.
- CAN-2409 granted FDA Fast Track Designation for NSCLC; topline overall survival data expected Q2 2024.
- CAN-3110 phase 1 recurrent HGG trial showed median OS of 11.8 months; repeat dosing arm enrolling.
- Initial overall survival data for CAN-2409 in borderline resectable pancreatic cancer expected Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023040980/0000950170-23-040980-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023040980/cadl-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040980

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer